A Case of BRCA2 Mutation-Positive Intraductal Carcinoma of the Prostate
A 75-year-old man presented with macroscopic hematuria and a high serum prostate-specific antigen (PSA) level. Macroscopic hematuria had subsided by the time of consultation. The PSA level was 38.590 ng/ml, which, along with rectal examination and magnetic resonance imaging findings, led to the susp...
| Veröffentlicht in: | Hinyokika kiyo. Acta urologica Japonica. - 1962. - 69(2023), 7 vom: 09. Juli, Seite 189-192 |
|---|---|
| 1. Verfasser: | |
| Weitere Verfasser: | , , , , , |
| Format: | Online-Aufsatz |
| Sprache: | Japanese |
| Veröffentlicht: |
2023
|
| Zugriff auf das übergeordnete Werk: | Hinyokika kiyo. Acta urologica Japonica |
| Schlagworte: | Case Reports English Abstract Journal Article cabazitaxel 51F690397J Prostate-Specific Antigen EC 3.4.21.77 BRCA2 protein, human BRCA2 Protein |
| Zusammenfassung: | A 75-year-old man presented with macroscopic hematuria and a high serum prostate-specific antigen (PSA) level. Macroscopic hematuria had subsided by the time of consultation. The PSA level was 38.590 ng/ml, which, along with rectal examination and magnetic resonance imaging findings, led to the suspicion of prostate cancer. Transrectal needle biopsy of the prostate revealed intraductal carcinoma of the prostate (IDC-P). Computed tomography and bone scintigraphy were performed, and the prostate cancer was classified as cT2cN0M0. After 6 months of combined androgen blockade therapy, a radical prostatectomy was performed; however, PSA levels continued to increase, and the patient was diagnosed with castration resistant prostate cancer. Multiple bone metastases appeared 5 months after the initiation of abiraterone therapy. Three courses of docetaxel and two courses of cabazitaxel were administered, but the disease progression continued. The IDC-P was found to be positive for the BRCA2 mutation by BRACAnalysis® performed at the start of cabazitaxel therapy. To our knowledge, no other cases of BRCA2 mutation positive IDC-P have been reported in Japan. After we started administration of Olaparib, the patient's PSA level was lowered and the disease progression stopped |
|---|---|
| Beschreibung: | Date Completed 11.08.2023 Date Revised 11.08.2023 published: Print Citation Status MEDLINE |
| ISSN: | 0018-1994 |
| DOI: | 10.14989/ActaUrolJap_69_7_189 |